Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423).

Divya V Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Matthew R. Cooperberg, Peter Carroll, Jonathan Chou, Hala Borno, Rohit Bose, Arpita Desai, Daniel H Kwon, Anthony C. Wong, Felix Y Feng, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin. Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e16510-e16510.